Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WUNGKI PARK

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1457617771
CMS profile
2780883
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,450.57

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,268.00 1
Travel and Lodging $1,050.69 3
Food and Beverage $131.88 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Regeneron Pharmaceuticals, Inc. $4,450.57 6

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WUNGKI PARK

NPI 1457617771 · CMS profile ID 2780883

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457617771?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WUNGKI PARK, NPI 1457617771, CMS profile ID 2780883. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457617771?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). WUNGKI PARK, NPI 1457617771, CMS profile ID 2780883. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457617771?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
WUNGKI PARK, NPI 1457617771, CMS profile ID 2780883, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1457617771?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $4,450.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Pharmaceuticals, Inc. $3,268.0012/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403281 CMS
Regeneron Pharmaceuticals, Inc. $911.6812/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403283 CMS
Regeneron Pharmaceuticals, Inc. $113.1412/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403285 CMS
Regeneron Pharmaceuticals, Inc. $25.8712/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403287 CMS
Regeneron Pharmaceuticals, Inc. $46.3012/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403289 CMS
Regeneron Pharmaceuticals, Inc. $85.5810/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114403279 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $126.78 1
PY2023 $110.78 1
PY2024 $4,450.57 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,772,986.59 668
PY2024 Principal investigator $4,393,777.13 199
PY2023 Principal investigator $5,266,392.43 164
PY2022 Principal investigator $5,283,436.36 4
PY2021 Principal investigator $3,810,346.16 3
PY2020 Principal investigator $930,010.08 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

199 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $2,509,969.61 12/31/2024 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
STUDY NAME#A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib POLAR for Individuals with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency No dispute reported 06/30/2026 1136442120
Principal investigator 1 Astellas Pharma Global Development $810.00 12/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1134123788
Principal investigator 1 Astellas Pharma Global Development $556.20 12/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1134123790
Principal investigator 1 Astellas Pharma Global Development $1,668.60 12/26/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1134123792
Principal investigator 1 Astellas Pharma Global Development $1,162.00 11/21/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1134123786
Principal investigator 1 Merck Sharp & Dohme LLC $215,331.53 11/18/2024 Non-covered Recipient Entity
MSK Ca Ctr IRB#20-481
A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib POLAR for Individuals with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency No dispute reported 06/30/2026 1136442039
Principal investigator 1 Amgen Inc. $132,400.87 10/24/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
AMG 193 Combo with IDE397 MAT2A No dispute reported 06/30/2026 1096307773
Principal investigator 1 Astellas Pharma Global Development $1,743.00 10/24/2024 Non-covered Recipient Entity
Memorial Sloan Kettering Cancer Center
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1134123784
Principal investigator 1 Astellas Pharma Inc $3,600.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597004
Principal investigator 1 Astellas Pharma Inc $2,907.13 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597006
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597008
Principal investigator 1 Astellas Pharma Inc $4,058.78 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597010
Principal investigator 1 Astellas Pharma Inc $4,529.09 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597012
Principal investigator 1 Astellas Pharma Inc $2,907.13 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597014
Principal investigator 1 Astellas Pharma Inc $3,600.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597016
Principal investigator 1 Astellas Pharma Inc $4,827.54 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597018
Principal investigator 1 Astellas Pharma Inc $1,513.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597020
Principal investigator 1 Astellas Pharma Inc $4,827.54 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597022
Principal investigator 1 Astellas Pharma Inc $1,607.46 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597024
Principal investigator 1 Astellas Pharma Inc $1,400.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597026
Principal investigator 1 Astellas Pharma Inc $1,489.63 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597028
Principal investigator 1 Astellas Pharma Inc $3,600.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597030
Principal investigator 1 Astellas Pharma Inc $6,481.28 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597032
Principal investigator 1 Astellas Pharma Inc $4,529.09 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597034
Principal investigator 1 Astellas Pharma Inc $810.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597036
Principal investigator 1 Astellas Pharma Inc $528.26 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597038
Principal investigator 1 Astellas Pharma Inc $810.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597040
Principal investigator 1 Astellas Pharma Inc $1,823.08 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597042
Principal investigator 1 Astellas Pharma Inc $810.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597044
Principal investigator 1 Astellas Pharma Inc $149.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597046
Principal investigator 1 Astellas Pharma Inc $1,061.45 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597048
Principal investigator 1 Astellas Pharma Inc $810.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597050
Principal investigator 1 Astellas Pharma Inc $149.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597052
Principal investigator 1 Astellas Pharma Inc $1,061.45 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597054
Principal investigator 1 Astellas Pharma Inc $446.85 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597056
Principal investigator 1 Astellas Pharma Inc $1,061.45 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597058
Principal investigator 1 Astellas Pharma Inc $446.85 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597060
Principal investigator 1 Astellas Pharma Inc $446.85 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597062
Principal investigator 1 Astellas Pharma Inc $149.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597064
Principal investigator 1 Astellas Pharma Inc $149.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597066
Principal investigator 1 Astellas Pharma Inc $446.85 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597068
Principal investigator 1 Astellas Pharma Inc $810.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597070
Principal investigator 1 Astellas Pharma Inc $446.85 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597072
Principal investigator 1 Astellas Pharma Inc $810.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597074
Principal investigator 1 Astellas Pharma Inc $149.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597076
Principal investigator 1 Astellas Pharma Inc $1,061.45 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597078
Principal investigator 1 Astellas Pharma Inc $149.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597080
Principal investigator 1 Astellas Pharma Inc $149.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597082
Principal investigator 1 Astellas Pharma Inc $1,513.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597084
Principal investigator 1 Astellas Pharma Inc $528.26 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597086
Principal investigator 1 Astellas Pharma Inc $528.26 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597088
Principal investigator 1 Astellas Pharma Inc $5,657.79 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597090
Principal investigator 1 Astellas Pharma Inc $810.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597092
Principal investigator 1 Astellas Pharma Inc $446.85 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597094
Principal investigator 1 Astellas Pharma Inc $149.00 10/03/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597096
Principal investigator 1 Amgen Inc. $58,360.60 09/21/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
AMG 193 Combo with IDE397 MAT2A No dispute reported 06/30/2026 1096307777
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596888
Principal investigator 1 Astellas Pharma Inc $4,769.08 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596890
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596892
Principal investigator 1 Astellas Pharma Inc $810.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596894
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596896
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596898
Principal investigator 1 Astellas Pharma Inc $810.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596900
Principal investigator 1 Astellas Pharma Inc $1,061.45 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596902
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596904
Principal investigator 1 Astellas Pharma Inc $810.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596906
Principal investigator 1 Astellas Pharma Inc $810.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596908
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596910
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596912
Principal investigator 1 Astellas Pharma Inc $810.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596914
Principal investigator 1 Astellas Pharma Inc $528.26 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596916
Principal investigator 1 Astellas Pharma Inc $1,061.45 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596918
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596920
Principal investigator 1 Astellas Pharma Inc $528.26 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596922
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596924
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596926
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596928
Principal investigator 1 Astellas Pharma Inc $810.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596930
Principal investigator 1 Astellas Pharma Inc $1,061.45 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596932
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596934
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596936
Principal investigator 1 Astellas Pharma Inc $810.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596938
Principal investigator 1 Astellas Pharma Inc $1,061.45 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596940
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596942
Principal investigator 1 Astellas Pharma Inc $810.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596944
Principal investigator 1 Astellas Pharma Inc $528.26 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596946
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596948
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596950
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596952
Principal investigator 1 Astellas Pharma Inc $810.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596954
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596956
Principal investigator 1 Astellas Pharma Inc $528.26 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596958
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596968
Principal investigator 1 Astellas Pharma Inc $528.26 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596970
Principal investigator 1 Astellas Pharma Inc $810.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596972
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596974
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596976
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596978
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596980
Principal investigator 1 Astellas Pharma Inc $810.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596982
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596984
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596986
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596988
Principal investigator 1 Astellas Pharma Inc $810.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596990
Principal investigator 1 Astellas Pharma Inc $528.26 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596992
Principal investigator 1 Astellas Pharma Inc $446.85 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596994
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596996
Principal investigator 1 Astellas Pharma Inc $149.00 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596998
Principal investigator 1 Astellas Pharma Inc $1,061.45 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597000
Principal investigator 1 Astellas Pharma Inc $1,061.45 08/30/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128597002
Principal investigator 1 Astellas Pharma Inc $2,000.00 08/08/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596960
Principal investigator 1 Astellas Pharma Inc $1,136.00 08/08/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596962
Principal investigator 1 Astellas Pharma Inc $601.50 08/08/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596964
Principal investigator 1 Astellas Pharma Inc $4,148.55 08/08/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596966
Principal investigator 1 Amgen Inc. $10,379.48 07/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
AMG 193 Combo with IDE397 MAT2A No dispute reported 06/30/2026 1096307779
Principal investigator 1 Astellas Pharma Inc $121.01 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596832
Principal investigator 1 Astellas Pharma Inc $1,607.46 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596834
Principal investigator 1 Astellas Pharma Inc $6,481.28 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596836
Principal investigator 1 Astellas Pharma Inc $1,513.00 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596838
Principal investigator 1 Astellas Pharma Inc $4,827.54 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596840
Principal investigator 1 Astellas Pharma Inc $1,400.00 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596842
Principal investigator 1 Astellas Pharma Inc $1,962.13 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596844
Principal investigator 1 Astellas Pharma Inc $4,769.08 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596846
Principal investigator 1 Astellas Pharma Inc $1,823.08 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596848
Principal investigator 1 Astellas Pharma Inc $4,529.09 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596850
Principal investigator 1 Astellas Pharma Inc $5,657.79 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596852
Principal investigator 1 Astellas Pharma Inc $4,827.54 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596854
Principal investigator 1 Astellas Pharma Inc $1,823.08 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596856
Principal investigator 1 Astellas Pharma Inc $4,529.09 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596858
Principal investigator 1 Astellas Pharma Inc $3,600.00 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596860
Principal investigator 1 Astellas Pharma Inc $2,907.13 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596862
Principal investigator 1 Astellas Pharma Inc $4,058.78 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596864
Principal investigator 1 Astellas Pharma Inc $3,600.00 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596866
Principal investigator 1 Astellas Pharma Inc $6,481.28 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596868
Principal investigator 1 Astellas Pharma Inc $3,600.00 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596870
Principal investigator 1 Astellas Pharma Inc $4,827.54 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596872
Principal investigator 1 Astellas Pharma Inc $1,513.00 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596874
Principal investigator 1 Astellas Pharma Inc $1,513.00 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596876
Principal investigator 1 Astellas Pharma Inc $4,769.08 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596878
Principal investigator 1 Astellas Pharma Inc $4,827.54 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596880
Principal investigator 1 Astellas Pharma Inc $4,769.08 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596882
Principal investigator 1 Astellas Pharma Inc $1,823.08 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596884
Principal investigator 1 Astellas Pharma Inc $1,823.08 07/10/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596886
Principal investigator 1 Merck Sharp & Dohme LLC $878,965.14 06/20/2024 Non-covered Recipient Entity
MSK Ca Ctr IRB#20-481
A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib POLAR for Individuals with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency No dispute reported 06/30/2026 1136442035
Principal investigator 1 Amgen Inc. $37,234.91 03/26/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
AMG 193 Combo with IDE397 MAT2A No dispute reported 06/30/2026 1096307775
Principal investigator 1 Astellas Pharma Inc $4,827.54 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596730
Principal investigator 1 Astellas Pharma Inc $1,823.08 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596732
Principal investigator 1 Astellas Pharma Inc $2,907.13 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596734
Principal investigator 1 Astellas Pharma Inc $3,600.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596736
Principal investigator 1 Astellas Pharma Inc $1,823.08 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596738
Principal investigator 1 Astellas Pharma Inc $1,823.08 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596740
Principal investigator 1 Astellas Pharma Inc $2,907.13 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596742
Principal investigator 1 Astellas Pharma Inc $1,513.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596744
Principal investigator 1 Astellas Pharma Inc $4,827.54 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596746
Principal investigator 1 Astellas Pharma Inc $4,827.54 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596748
Principal investigator 1 Astellas Pharma Inc $1,607.46 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596750
Principal investigator 1 Astellas Pharma Inc $4,529.09 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596752
Principal investigator 1 Astellas Pharma Inc $1,513.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596754
Principal investigator 1 Astellas Pharma Inc $1,823.08 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596756
Principal investigator 1 Astellas Pharma Inc $1,513.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596758
Principal investigator 1 Astellas Pharma Inc $3,600.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596760
Principal investigator 1 Astellas Pharma Inc $3,600.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596762
Principal investigator 1 Astellas Pharma Inc $6,481.28 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596764
Principal investigator 1 Astellas Pharma Inc $4,827.54 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596766
Principal investigator 1 Astellas Pharma Inc $4,769.08 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596768
Principal investigator 1 Astellas Pharma Inc $4,827.54 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596770
Principal investigator 1 Astellas Pharma Inc $1,400.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596772
Principal investigator 1 Astellas Pharma Inc $1,513.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596774
Principal investigator 1 Astellas Pharma Inc $6,481.28 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596776
Principal investigator 1 Astellas Pharma Inc $6,481.28 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596778
Principal investigator 1 Astellas Pharma Inc $4,529.09 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596780
Principal investigator 1 Astellas Pharma Inc $4,827.54 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596782
Principal investigator 1 Astellas Pharma Inc $3,600.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596784
Principal investigator 1 Astellas Pharma Inc $5,657.79 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596786
Principal investigator 1 Astellas Pharma Inc $1,607.46 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596788
Principal investigator 1 Astellas Pharma Inc $4,827.54 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596790
Principal investigator 1 Astellas Pharma Inc $1,823.08 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596792
Principal investigator 1 Astellas Pharma Inc $2,907.13 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596794
Principal investigator 1 Astellas Pharma Inc $1,823.08 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596796
Principal investigator 1 Astellas Pharma Inc $3,600.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596798
Principal investigator 1 Astellas Pharma Inc $4,827.54 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596800
Principal investigator 1 Astellas Pharma Inc $4,827.54 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596802
Principal investigator 1 Astellas Pharma Inc $121.01 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596804
Principal investigator 1 Astellas Pharma Inc $1,823.08 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596806
Principal investigator 1 Astellas Pharma Inc $3,600.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596808
Principal investigator 1 Astellas Pharma Inc $4,769.08 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596810
Principal investigator 1 Astellas Pharma Inc $3,600.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596812
Principal investigator 1 Astellas Pharma Inc $5,657.79 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596814
Principal investigator 1 Astellas Pharma Inc $1,513.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596816
Principal investigator 1 Astellas Pharma Inc $4,529.09 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596818
Principal investigator 1 Astellas Pharma Inc $1,823.08 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596820
Principal investigator 1 Astellas Pharma Inc $4,827.54 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596822
Principal investigator 1 Astellas Pharma Inc $4,058.78 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596824
Principal investigator 1 Astellas Pharma Inc $1,513.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596826
Principal investigator 1 Astellas Pharma Inc $1,400.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596828
Principal investigator 1 Astellas Pharma Inc $3,600.00 03/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596830
Principal investigator 1 Merck Sharp & Dohme LLC $149,999.85 03/18/2024 Covered Recipient Teaching Hospital
Our Lady Of The Lake Rmc
A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib POLAR for Individuals with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency No dispute reported 06/30/2026 1136442116
Principal investigator 1 Astellas Pharma Inc $3,600.00 01/25/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596728
Principal investigator 1 Astellas Pharma Inc $3,600.00 01/22/2024 Non-covered Recipient Entity
MEMORIAL SLOAN KETTERING CANCER CENTER
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1128596726